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- hemophagocytic lymphohistiocytosis, MLST - multi-locus sequence type, PTLD - posttransplant lymphoproliferative disorder.

ABSTRACT:

‘Cepacia syndrome’ caused by Burkholderia cepacia complex and often found to be
associated in patients with cystic fibrosis, carries a high mortality rate. It is rare for

Burkholderia multivorans, a species within the Burkhoderia cepacia complex to cause
‘cepacia syndrome’ even among the cystic fibrosis patients. This is the first reported
fatal case of ‘cepacia syndrome’ caused by Burkholderia multivorans occurring in a noncystic fibrosis pediatric liver transplant recipient. We describe the unique
characteristics of this pathogen among the non-cystic fibrosis population and the
importance of early recognition and treatment.
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The Burkholderia cepacia complex (Bcc), consisting of 22 species, is a group of aerobic,
Gram-negative, non-spore-forming bacilli that are phenotypically similar but
genotypically distinct(1). Bcc are well recognized opportunistic pathogens associated
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with high morbidity and mortality in persons with cystic fibrosis (CF)(2). Bcc infections
in non-CF settings have been described in nosocomial outbreaks attributable to
contaminated disinfectants, intravenous solutions, and medical devices, and in
opportunistic infections in immunocompromised hosts such as patients with chronic
granulomatous disease (CGD) or malignancies(2-4). ‘Cepacia syndrome’, a necrotizing
pneumonia characterized by rapid clinical deterioration and septicemia frequently
leading to death(5), has mostly been associated with Burkholderia cenocepacia, a Bcc
species, isolated most commonly in CF patients(2). Cases of cepacia syndrome
secondary to Burkholderia multivorans have been described infrequently(6-8), but no
cases have been reported in the literature outside of the CF population.

We present the first report of a case of cepacia syndrome caused by B. multivorans in a
pediatric liver transplant recipient and briefly review the literature on Bcc infection in the
non-CF setting.

A 23-month old Caucasian male, post-liver transplant was transferred from a tertiary
children’s hospital to our transplant center with persistent fever of unknown cause. His
past medical history included biliary atresia and Kasai surgery at 58 days of age. He had
normal newborn screening and sweat test. His clinical course was complicated by
ascending cholangitis, worsening jaundice and recurrent ascites with progression to
end-stage liver disease requiring a living-related liver transplant from his father at 6
months of age. Donor and recipient were both positive for Epstein-Barr virus (EBV) IgG,
while both donor and recipient serostatus for cytomegalovirus was negative. He was
placed on standard immunosuppression with steroid and tacrolimus post-transplant.
He was weaned off steroids three months post-transplant. At 12 months of age, he
developed intestinal polymorphous post-transplant lymphoproliferative disorder
(PTLD). Serum EBV quantitative PCR became undetectable after four doses of
rituximab, and tacrolimus was restarted targeting a serum level between 3-4ug/L. He
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remained well apart from a single episode of perianal abscess, treated with a 3-week
course of amoxicillin/clavulanic acid.
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The current illness began with fever presenting to his local community hospital. He was
subsequently transferred to his local academic hospital for ongoing recurrent fever
after receiving 4 days of cefotaxime. At the local academic hospital, he was empirically
treated with intravenous piperacillin/tazobactam and tobramycin before his blood
culture (BC) became positive for Bcc, at which time his therapy was switched to
ceftazidime and ciprofloxacin, to which the Bcc isolate was susceptible (See Figure 2). A
central venous line (CVL) was inserted due to difficult intravenous access after the BC
became negative, and his antibiotics were continued for another 2 weeks. Other
investigations, including cerebrospinal fluid and urine culture, chest x-ray, head CT
scan, and an abdominal ultrasound were all unremarkable. He had a single recurrence
of fever, which was attributable to a possible viral infection on the last day of
antimicrobial therapy and he was given piperacillin/tazobactam and tobramycin for an
additional 48 hours until repeat BC was negative. His CVL was removed prior to
discharge. Given repeatedly negative BCs and a recent serum EBV viral load of
5.6x103 copies per mL, PTLD was suspected as a potential etiology of the recurrent fever
within 5 days of discharge. Tacrolimus levels were measured between 2-3ug/L before
discontinuation. Endoscopic assessment with luminal biopsies, however, showed no
evidence of EBV encoded RNA by in situ hybridization. Another CVL was inserted. A
chest x-ray taken at his initial hospital admission was reported as unremarkable.
However, a repeat chest x-ray prior to transfer showed small patchy opacities in both
lungs fields.

At our institution, he remained febrile. Physical examination was unremarkable except
for mildly enlarged tonsils. There was no lymphadenopathy or palpable abdominal
masses, and his chest was clear. Within 24 hours, however, he quickly deteriorated,
developing septic shock and required oxygen supplementation. Meropenem and
vancomycin were commenced to broaden coverage in the context of an
immunocompromised patient who failed empiric therapy with pipercillin/tazobactam,
ceftazidime and ciprofloxacin. Repeat chest x-ray showed worsening diffuse, ill-defined
nodular densities in both lungs suggesting the possibility of disseminated fungal
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infection (Figure 1A) and amphotericin B was added. The CVL was removed after both
peripheral and CVL BCs simultaneously became positive for Bcc, which was later
identified to be B. multivorans. Despite broadening antimicrobials to include
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ciprofloxacin and sulfamethoxazole/trimethoprim, his condition worsened and he died
from disseminated intravascular coagulation, multi-organ failure and secondary
hemophagocytic lymphohistiocytosis (HLH).

Postmortem examination revealed necrotic abscesses in both lungs (Figure 1B-1D) and
most organs, including liver, lymph nodes, bone marrow, brain, spleen, kidneys and
adrenal glands. Lung tissue culture grew B. multivorans. Hemophagocytosis was seen
in the liver confirming the clinical suspicion of secondary HLH. A large, recent
intracerebral hemorrhage of the left cerebral hemisphere was also observed, which was
negative for bacteria and fungal elements on Gram and Gormori methenamine silver
stain. There was no pathological evidence to suggest the presence of PTLD, liver
allograft rejection, CGD, or CF.

Further molecular typing of the B. multivorans isolate revealed that it was most closely
related to a multi-locus sequence type (MLST)(9), ST355, which had only been
previously identified from the blood culture of a patient with CGD in the United
States(10). Our patient’s isolate differed by random amplified polymorphic DNA
analysis(11) and was just one base pair different in one of the 7 MLST alleles tested
compared to the isolate from the CGD patient. Repetitive extragenic palindromic PCR
using BOX A1R primer(12), however, found these two isolates to be identical.

To our knowledge, this is the first report of B. multivorans infection presenting as
‘cepacia syndrome’ in a non-CF liver transplant patient. Increased awareness of the
severity of this condition amongst transplant physicians may lead to more rapid
diagnosis with close monitoring and frequent follow-up, and longer duration of
antibiotic therapy.

We performed a literature review of cases of Bcc infections in non-CF and non-outbreak
settings by searching the Medline database since 1996 using the terms “Burkholderia”
and “non-cystic fibrosis”. A total of 17 cases were identified (Table 1); most were case
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reports(3, 13-19) and one was a prospective observational study(4). Species
identification was only available for 3 patients; two involved B. cenocepacia and one
with B. multivorans(16, 19). Four cases (Patient 2, 3, 8 and 12 in Table 1) fit the clinical
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presentation of ‘cepacia syndrome’ as characterized by rapid respiratory decline with
bacteremia and necrotizing pneumonia. Two of these patients had underlying CGD. All
were fatal except one (Patient 8).

The incidence of B. multivorans infection has been increasing in CF patients, but it is a
rarely seen infection in the non-CF population(10). In one New Zealand study, B.

multivorans accounted for 79.5% of Bcc infections in CF patients, but only 28% in the
non-CF group(20). Burkholderia lata and Burkholderia stabilis, with low level of
diversity based on MLST, accounted for 44% of the non-CF Bcc infections in the
study(20). In contrast to B. cenocepacia where patient-to-patient transmission has been
well described in CF in the past, initial B. multivorans infection in CF patients is thought
to be acquired from the environment(21). Among the non-CF group, it is thought that
person-to-person spread is unlikely, as the infected patients were separated temporally
and geographically with no epidemiological links(10, 20). Infection control precautions
should be no different for immunosuppressed patients.

In our case, although the patient had a liver transplantation that may have contributed
to the development of this infection, he was only on minimal immunosuppression at the
time of infection. His rapid clinical deterioration is uncharacteristic for B. multivorans
infections in a non-CF setting. The underlying reason for the severity of his illness and
source of infection remain unclear. The incidence of Bcc infection in transplant patients
is unknown. Recognition of chest x-ray changes (Figure 1A), in the setting of recent Bcc
bacteremia, should alert transplant physicians to possible cepacia syndrome. Despite
the recognition of the clinical significance of Bcc infections in both
immunocompromised and CF patients, there is a lack of evidenced based antibiotic
treatment for this infection(22, 23). Because of the potential for emergence of
resistance while on monotherapy and data from synergy studies, some would consider
treatment with multiple intravenous antibiotics initially, follow by two to three drug
combination when susceptibility of the Bcc is available. Although the exact duration of
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therapy is not clear, the possibility of cepacia syndrome may suggest the need for a
longer duration of antibiotics with close monitoring.
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This is the first case report of B. multivorans presenting as ‘cepacia syndrome’ in a nonCF pediatric liver transplant recipient. Early recognition and appropriate treatment is
crucial.
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FIGURE LEGEND

Figure 1: Imaging, autopsy and histology findings of ‘cepacia syndrome’.
A. Chest x-ray showed diffusely ill-defined density nodules in bilateral lungs and
small right pleural effusion.
B. Autopsy revealed diffuse multiple foci of necrotic abscesses (red arrow) within
both lungs.

C. Image shows histiocytes at the periphery and karyorrhectic debris toward the
center of the abscess.
D. Immunohistochemical staining for CD68 (Dako, Carpinteria,CA) confirming
marked numbers of histiocytes at the periphery of the lung abscess.
Figure 2: Clinical events with key investigation findings and treatment course (including
Bcc susceptibility results).
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TABLE:
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Table 1: Review of the literature of Bcc infections in non-CF population.

Authors

Lacy et al.

Belchis et al

Acute
Patient

Age(y)

Underlying Medical

Bcc

Bcc

Necrotizing

Respiratory

no.

, Sex

Conditions

Species

Bacteremia

Pneumonia

Decline

Sepsis

Outcome

1

3.5, M

CGD

unknown

Y

unclear (pleural

Y

Y

died

effusion)
2

0.6, M

CGD

unknown

Y

Y

Y

Y

died

3

44, M

Pulmonary

unknown

Y

Y

Y

Y

died

unknown

N

Y

Y

unclear

died

unknown

N

Y

Y

unclear

died

histoplasmosis,
chronic bronchitis,
recurrent childhood
infections
4

40, F

Salmonella paratyphi
B pneumonia,
maxillary sinusitis,
asthma

5

43, F

Lupus-like syndrome;
migraines;
hypothyroidism

Sirinavain et al.

6

1.4, M

CGD

unknown

N

Y

Y

Y

recovered

Whitehouse et

7

40, F

Mannose binding lectin

B.

N

Y

N

N

recovered

deficiency

multivorans

CGD

unknown

Y

Y

Y

Y

recovered

al.

Hisano et al.

8

29, F
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Satpute et al.

9

2, M

healthy

B.

Y

N

N

Y

recovered

Y

N

N

Y

recovered
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cenocepaci
a
10

9, M

immunocompromised

B.
cenocepaci
a

Suresh et al.

11

63, M

healthy

unknown

N

Y

N

unclear

recovered

Hauser et al.

12

64, M

HT, Type 2-DM

unknown

Y

Y

Y

Y

died

Martino et al.

13

*

malignancies

unknown

Y

Y

unknown

Y

died

14

*

malignancies

unknown

Y

Y

unknown

Y

recovered

15

*

malignancies

unknown

Y

N

unknown

N

recovered

16

*

malignancies

unknown

Y

N

unknown

N

recovered

17

*

malignancies

unknown

Y

N

unknown

N

recovered

* Prospective trial, specific age and sex of patients not available
y, year; M, male; F, female; HT, hypertension; Type-2 DM, Type-2 Diabetes Mellitus; CGD, Chronic Granulomatous Disease; N, No; Y, Yes;
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FIGURE:
Figure 1: Imaging, autopsy and histology findings of ‘cepacia syndrome’. (A) Chest x-ray
showed diffusely ill-defined density nodules in bilateral lungs and small right pleural
effusion. (B) Autopsy revealed diffuse multiple foci of necrotic abscesses (red arrow)
within both lungs. (C-D) Photomicrographs of lung abscess. (C) Image shows histiocytes
at the periphery and karyorrhectic debris toward the center of the abscess. [H&E,
original magnification x 100] (D) Immunohistochemical staining for CD68 (Dako,
Carpinteria,CA) confirming marked numbers of histiocytes at the periphery of the lung
abscess. [immunohistochemistry for CD68, original magnification x 100]

A

B
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FIGURE:
Figure 2: Clinical events with key investigation findings and treatment course (including
Bcc susceptibility results).

PTLD, Post-transplant Lymphoproliferative Disorder; S, Sensitive; R, Resistant; BC,
Blood Culture; CVL, Central Venous Line; Bcc, Burkholderia cepacia complex; CXR, Chest
X-ray.
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